Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on Friday, May 30, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward medical oncologists, NPs/PAs, nurses, pharmacists, and other HCPs involved in the treatment and management of gliomas in pediatric and adult patients.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate recent classification criteria and diagnostic strategies for the identification of adult and pediatric patients with glioma.
- Incorporate genetic and molecular information to accurately classify gliomas and develop personalized treatment plans.
- Appraise recent developments in targeted, immunotherapeutic, and other novel therapeutic approaches, including potential implications of investigational approaches in the care of patients with gliomas.
- Determine strategies to integrate targeted and immunotherapeutic approaches and assess the potential implications of emerging novel approaches in the management of pediatric gliomas.
Vinay K. Puduvalli, MD
Professor and Chair, Department of Neuro-Oncology
Co-Director, Cancer Neuroscience Program
Co-Director, NeuroHealth Initiative
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisory Board: Boehringer Ingelheim, Guidepoint, Novocure, Servier, Tango Therapeutics, Telix Pharmaceuticals, Orbus Therapeutics; Honorarium: Boehringer Ingelheim, Guidepoint, Novocure, Servier, Tango Therapeutics, Telix Pharmaceuticals, Orbus Therapeutics.
Manmeet Ahluwalia, MD, MBA
Professor of Translational Medicine
Herbert Wertheim College of Medicine, Florida International University
Fernandez Family Foundation Endowed Chair in Cancer Research
Chief of Medical Oncology
Chief Scientific Officer & Deputy Director
Miami Cancer Institute, Baptist Health South Florida
Miami, FL
Disclosures : Consultant: AnHeart Therapeutics, Apollomics, Bayer, Menarini Ricerche, TherAguix, Varian Medical Systems, ViewRay, Xoft.
Stephen J. Bagley, MD, MSCE
Assistant Professor of Medicine and Neurosurgery
Section Chief
Neuro-Oncology Section
Division of Hematology/Oncology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
Disclosures: Advisor: Modifi Bio, Servier, Telix; Researcher: GSK, Incyte, Kite (a Gilead company), Lilly, Novocure.
Angela Waanders, MD, MPH, MS
Associate Professor of Pediatrics (Hematology, Oncology, and Stem Cell Transplantation)
Section Head, Neuro-Oncology
Director, Precision Medicine Oncology
Gus Foundation Chair in Neuro-Oncology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures: Ad Hoc Consultant: DayOne, Ipsen; Chair: Alexion; Member: DayOne; Scientific Advisory Board: Alexion, Day One; Selumetinib Registry: Alexion.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here